Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - EirGenix

Next Previous
Drug Profile

Trastuzumab biosimilar - EirGenix

Alternative Names: EG-12014; EGI 014A1; EGI-014; EIRGASUN; HERWENDA; Trastuzumab biosimilar; Trastuzumab biosimilar-EirGenix

Latest Information Update: 21 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EirGenix
  • Developer EirGenix; Sandoz
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Registered Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 22 Nov 2023 EirGenix plans to launch Trastuzumab in Europe for the treatment of HER-2 positive breast cancer in 2024
  • 22 Nov 2023 Registered for HER2-positive-breast-cancer in Norway, Iceland, Liechtenstein (Combination therapy, Early-stage disease, Neoadjuvant therapy) (IV)
  • 22 Nov 2023 Registered for Gastric cancer (Metastatic disease) in European Union (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top